Bristol-Myers Squibb (BMY) Tops Q3 EPS by 22c, Offers Guidance
Tweet
Share
E-mail
Get Alerts BMY Hot Sheet
Price: $55.53 +1.52%
Revenue Growth %: -4.6%
Financial Fact:
Marketing, selling and administrative: 1.14B
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: -4.6%
Financial Fact:
Marketing, selling and administrative: 1.14B
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Bristol-Myers Squibb (NYSE: BMY) reported Q3 EPS of $2.00, $0.22 better than the analyst estimate of $1.78. Revenue for the quarter came in at $11 billion versus the consensus estimate of $10.98 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2023 EPS of $7.50-$7.65, versus the consensus of $7.36.
For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- After-Hours Stock Movers: FDX, CBRS, NKE
- Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
